Contribute Try STAT+ Today

Top of the morning to you and a fine one, it is. A shiny sun and gusty winds make for a lovely view from the official Pharmalot campus corner office. Yes, we have a corner office. We also have a coffee kettle, so please join us as we brew a cup of stimulation. This is, you know, the middle of the week, which means there is much to do. No doubt, you can relate on some level. So time to get cracking. As always, here is the latest grab bag of items of interest to help you along. Hope you conquer the world today and do stay in touch.

Vaccine affordability has emerged as a final roadblock to getting a deal on billions in funding to combat the coronavirus, The Hill reports. Congressional negotiators hope to unveil a funding deal soon, but as of Tuesday evening, lawmakers and top staff were haggling over the final sticking points. Democrats are pushing to include cost controls on vaccines or testing kits developed in response to the coronavirus as they prepare to sign off on billions of new funding.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.